Indolent lymphoma · 3 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Bendamustine and Obinutuzumab Variant #02 | — | R 101 593 | 28d | — | — | 6 | R 227 981 PFS proxy | 2 |
Obinutuzumab monotherapy Variant #06 | — | R 23 849 | 21d | — | — | ~12 | ~R 286 185 indirect | — |
Bendamustine monotherapy Variant #01 | — | R 7 084 | — | 13.8 mo | — | 6 | R 42 504 PFS proxy | 1 |
3 of 3 regimens shown